An individualized GH dose regimen for long-term GH treatment in Japanese patients with adult GH deficiency

European Journal of Endocrinology

Volumn 153, Issue 1, 2005, Pages 57-65

  Chihara, Kazuo ^a   Koledova, Ekaterina ^b   Shimatsu, Akira ^c   Kato, Yuzuru ^d   Kohno, Hitoshi ^e   Tanaka, Toshiaki ^f   Teramoto, Akira ^g   Bates, Peter C ^h   Attanasio, Andrea F ⁱ  

^a KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b ELI LILLY AND COMPANY   (United States)

^c NATIONAL HOSPITAL ORGANIZATION KYOTO MEDICAL CENTER   (Japan)

^d SHIMANE UNIVERSITY   (Japan)

^e FUKUOKA CHILDREN S HOSPITAL   (Japan)

^f NATIONAL CENTER FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^g NIPPON MEDICAL SCHOOL   (Japan)

^h Cambridge Medical Writing Services   (United Kingdom)

ⁱ Cascina del Rosone ^*  (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN GROWTH HORMONE; LIPID; PLACEBO; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BODY FAT; BODY MASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CRANIOPHARYNGIOMA; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; EDEMA; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE DEFICIENCY; HEADACHE; HUMAN; JAPAN; LONG TERM CARE; MALE; MEDIASTINUM DISEASE; METABOLIC DISORDER; MUSCULOSKELETAL DISEASE; NAUSEA; NEUROLOGIC DISEASE; ONSET AGE; PHARYNX DISEASE; PRIORITY JOURNAL; PRURITUS; RESPIRATORY TRACT DISEASE; RHINOPHARYNGITIS; RHINORRHEA; SIDE EFFECT; SKIN DISEASE; SPUTUM; THORAX DISEASE; TREATMENT OUTCOME;

ADULT; CHOLESTEROL; FEMALE; HUMAN GROWTH HORMONE; HUMANS; HYPOPITUITARISM; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; INSULIN-LIKE GROWTH FACTOR I; JAPAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

EID: 22744437503     PISSN: 08044643     EISSN: None     Source Type: Journal    
DOI: 10.1530/eje.1.01936     Document Type: Article

References (24)

1. Growth Hormone Research Society. Consensus guidelines for the diagnosis and treatment of adults with growth hormone deficiency: summary statement of the Growth Hormone Research Society workshop on adult growth hormone deficiency. Journal of Clinical Endocrinology and Metabolism 1998 83 379-381.
2. Gibney J, Wallace JD, Spinks T, Schnorr L, Ranicar A, Cuneo RC, Lockhart S, Burnand KG, Salomon F, Sonksen PH & Russell-Jones D. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. Journal of Clinical Endocrinology and Metabolism 1999 84 2596-2602.
3. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B & Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. Journal of Clinical Endocrinology and Metabolism 2004 89 2192-2199.
4. Chihara K, Koledova E, Shimatsu A, Kato Y, Kohno H, Tanaka T, Teramoto A, Bates PC & Attanasio AF. Adult GH deficiency in Japanese patients: effects of GH treatment in a randomised, placebo-controlled trial. European Journal of Endocrinology 2004 151 343-350.
5. Shimatsu A. Recent progress in the diagnosis of growth hormone (GH) disorders [in Japanese]. Japanese Journal of Clinical Pathology 1997 45 837-843.
6. Critical evaluation of the safety of recombinant human growth hormone administration: statement from the Growth Hormone Research Society. Journal of Clinical Endocrinology and Metabolism 2001 86 1868-1870.
7. The Examination Committee of Criteria for 'Obesity Disease' in Japan, Japan Society for the Study of Obesity, New criteria for 'obesity disease' in Japan. Circulation Journal 2002 66 987-992.
8. Ito H, Nakasuga K, Oshima A, Maruyama T, Kaji Y, Harada M, Fukunaga M, Jingu S & Sakamoto M. Detection of cardiovascular risk factors by indices of obesity obtained from anthropometry and dual energy X-ray absorptiometry in Japanese individuals. International Journal of Obesity 2003 27 232-237.
9. Murray RD. Adult growth hormone replacement: current understanding. Current Opinion in Pharmacology 2003 3 642-649.
10. Hoffman AR, Strasburger CJ, Zagar A, Blum WF, Kehely A & Hartman ML. Efficacy and tolerability of an individualized dosing regimen for adult growth hormone replacement therapy in comparison with fixed body weight-based dosing. Journal of Clinical Endocrinology and Metabolism 2004 89 3224-3233.
11. Feldt-Rasmussen U, Wilton P & Jonsson P. KIMS Study Group; KIMS International Board. Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Hormone and IGF Research 2004 14 (Suppl A) S51-S58.
12. Kehely A, Bates PC, Frewer P, Birkett M, Blum WF, Mamessier P, Ezzat S, Ho KK, Lombardi G, Luger A, Marek J, Russell-Jones D, Sonksen P, & Attanasio AF. Short-term safety and efficacy of human GH replacement therapy in 595 adults with GH deficiency: a comparison of two dosage algorithms. Journal of Clinical Endocrinology and Metabolism 2002 87 1974-1979.
13. Bengtsson BA, Eden S, Loon L, Kvist H, Stokland A, Lindstedt G, Bosaeus I, Tolli J, Sjostrom L & Isaksson OG. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. Journal of Clinical Endocrinology and Metabolism 1993 76 309-317.
14. Irie M, Kato Y & Takano K. Phase III study of recombinant human growth hormone for growth hormone deficiency in adults. Japanese Pharmacology and Therapeutics 1997 25 223-235.
15. De Boer H, Blok GJ & van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocrine Reviews 1995 16 63-86.
16. Florakis D, Hung V, Kaltsas G, Coyte D, Jenkins PJ, Chew SL, Grossman AB, Besser GM & Monson JP. Sustained reduction in circulating cholesterol in adult hypopituitary patients given low dose titrated growth hormone replacement therapy. A two year study. Clinical Endocrinology 2000 53 453-459.
17. Murray RD, Wieringa GE, Lissett CA, Darzy KH, Smethurst LE & Shalet SM. Low-dose GH replacement improves the adverse lipid profile associated with the adult GH deficiency syndrome. Clinical Endocrinology 2002 56 525-532.
18. Suka M, Sugimori H & Yoshida K. Validity of the Framingham risk model applied to Japanese men. Methods of Informatic Medicine 2002 41 213-215.
19. Twickler TB, Cramer MJ, Dallinga-Thie GM, Chapman MJ, Erkelens DW & Koppeschaar HP. Adult-onset growth hormone deficiency: relation of postprandial dyslipidemia to premature atherosclerosis. Journal of Clinical Endocrinology and Metabolism 2003 88 2479-2488.
20. Kuromaru R, Kohno H, Ueyama N, Hassan HMS, Honda S & Hara T. Long-term prospective study of body composition and lipid profiles during and after growth hormone (GH) treatment in children with GH deficiency: gender-specific metabolic effects. Journal of Clinical Endocrinology and Metabolism 1998 83 3890-3896.
21. Kuromaru R, Kohno H & Hara T. Changes in adiposity and excess body weight correlate with growh responses but not with decreases in low-density lipoprotein cholesterol levels during GH treatment in GH-deficient children. Clinical Endocrinology 2002 56 799-803.
22. Chipman JJ, Attanasio AF, Birkett MA, Bates PC, Webb S & Lamberts SWJ. The safety profile of GH replacement therapy in adults. Clinical Endocrinology 1997 46 473-481.
23. Jørgensen JOL, Thuesen L, Müller J, Ovesen P, Skakkebaek NE & Christiansen JS. Three years of growth hormone treatment in growth hormone-deficient adults: near normalization of body composition and physical performance. European Journal of Endocrinology 1994 130 224-228.
24. 4 therapy become mandatory? Journal of Clinical Endocrinology and Metabolism 2002 87 2042-2045.